Medistim ASA (Norway) Performance
| MEDI Stock | NOK 148.00 7.00 4.96% |
The company secures a Beta (Market Risk) of -0.64, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Medistim ASA are expected to decrease at a much lower rate. During the bear market, Medistim ASA is likely to outperform the market. At this point, Medistim ASA has a negative expected return of -0.13%. Please make sure to verify Medistim ASA's coefficient of variation, jensen alpha, treynor ratio, as well as the relationship between the standard deviation and total risk alpha , to decide if Medistim ASA performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Medistim ASA has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest conflicting performance, the Stock's essential indicators remain persistent and the latest mess on Wall Street may also be a sign of long-standing gains for the company institutional investors. ...more
| Begin Period Cash Flow | 71.9 M | |
| Total Cashflows From Investing Activities | -11.5 M |
Medistim |
Medistim ASA Relative Risk vs. Return Landscape
If you would invest 16,400 in Medistim ASA on August 26, 2024 and sell it today you would lose (1,600) from holding Medistim ASA or give up 9.76% of portfolio value over 90 days. Medistim ASA is generating negative expected returns and assumes 2.4729% volatility on return distribution over the 90 days horizon. Simply put, 22% of stocks are less volatile than Medistim, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Medistim ASA Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Medistim ASA's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Medistim ASA, and traders can use it to determine the average amount a Medistim ASA's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0507
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | MEDI |
Estimated Market Risk
| 2.47 actual daily | 21 79% of assets are more volatile |
Expected Return
| -0.13 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.05 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Medistim ASA is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Medistim ASA by adding Medistim ASA to a well-diversified portfolio.
Medistim ASA Fundamentals Growth
Medistim Stock prices reflect investors' perceptions of the future prospects and financial health of Medistim ASA, and Medistim ASA fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Medistim Stock performance.
| Return On Equity | 0.31 | |||
| Return On Asset | 0.2 | |||
| Profit Margin | 0.21 % | |||
| Operating Margin | 0.27 % | |||
| Current Valuation | 4.12 B | |||
| Shares Outstanding | 18.26 M | |||
| Price To Earning | 36.32 X | |||
| Price To Book | 12.24 X | |||
| Price To Sales | 9.15 X | |||
| Revenue | 417.82 M | |||
| EBITDA | 137.68 M | |||
| Cash And Equivalents | 129.49 M | |||
| Cash Per Share | 2.99 X | |||
| Total Debt | 17.08 M | |||
| Debt To Equity | 3.40 % | |||
| Book Value Per Share | 18.94 X | |||
| Cash Flow From Operations | 128.14 M | |||
| Earnings Per Share | 5.34 X | |||
| Total Asset | 403.24 M | |||
| Current Asset | 136 M | |||
| Current Liabilities | 43 M | |||
About Medistim ASA Performance
By examining Medistim ASA's fundamental ratios, stakeholders can obtain critical insights into Medistim ASA's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Medistim ASA is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Medistim ASA develops, produces, services, leases, and distributes medical devices for cardio-vascular surgery in the United States, Europe, Asia, and internationally. Medistim ASA was founded in 1984 and is headquartered in Oslo, Norway. MEDISTIM ASA operates under Medical Equipment classification in Norway and is traded on Oslo Stock Exchange. It employs 105 people.Things to note about Medistim ASA performance evaluation
Checking the ongoing alerts about Medistim ASA for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Medistim ASA help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Medistim ASA generated a negative expected return over the last 90 days | |
| About 74.0% of the company shares are owned by institutional investors |
- Analyzing Medistim ASA's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Medistim ASA's stock is overvalued or undervalued compared to its peers.
- Examining Medistim ASA's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Medistim ASA's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Medistim ASA's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Medistim ASA's stock. These opinions can provide insight into Medistim ASA's potential for growth and whether the stock is currently undervalued or overvalued.
Other Information on Investing in Medistim Stock
Medistim ASA financial ratios help investors to determine whether Medistim Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Medistim with respect to the benefits of owning Medistim ASA security.